Table 2.
Model-adjusted risks of early interferon therapy
| Estimate (95% CI) | ||||||
|---|---|---|---|---|---|---|
| Risk type | Outcome | Model | No GC (n = 174) | P-value | With GC (n = 200) | P-value |
| Hazard ratio | Hospital discharge | Cox proportional hazardsa | 0.81 (0.59–1.12) | 0.197 | 1.68 (1.19–2.37) | 0.003 |
| Hazard ratio | Symptom relief | Cox proportional hazardsa | 0.87 (0.64–1.19) | 0.377 | 1.48 (1.06–2.08) | 0.023 |
| Odds ratio | Prolonged viral shedding | Logistic regressiona | 2.05 (0.88–4.74) | 0.096 | 0.24 (0.10–0.57) | 0.001 |
GC glucocorticoids, CI confidence interval
aModel adjusted for gender, hypertension, diabetes, oxygen saturation at admission, symptom count at admission, lopinavir/ritonavir, oseltamivir, and umifenovir use. Cox models were fitted to all survivors, and logistic regression were fitted to patients ceased viral shedding before discharge or death